PL4094766T3 - Doustna kombinacja o ustalonej dawce i jej zastosowanie w leczeniu mięśniaków macicy i endometriozy - Google Patents
Doustna kombinacja o ustalonej dawce i jej zastosowanie w leczeniu mięśniaków macicy i endometriozyInfo
- Publication number
- PL4094766T3 PL4094766T3 PL22162349.9T PL22162349T PL4094766T3 PL 4094766 T3 PL4094766 T3 PL 4094766T3 PL 22162349 T PL22162349 T PL 22162349T PL 4094766 T3 PL4094766 T3 PL 4094766T3
- Authority
- PL
- Poland
- Prior art keywords
- endometriosis
- treatment
- fixed dose
- dose combination
- uterine fibroids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402034P | 2016-09-30 | 2016-09-30 | |
| US201662402055P | 2016-09-30 | 2016-09-30 | |
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| US201762492839P | 2017-05-01 | 2017-05-01 | |
| US201762528409P | 2017-07-03 | 2017-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4094766T3 true PL4094766T3 (pl) | 2025-07-28 |
Family
ID=60915460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22162349.9T PL4094766T3 (pl) | 2016-09-30 | 2017-09-29 | Doustna kombinacja o ustalonej dawce i jej zastosowanie w leczeniu mięśniaków macicy i endometriozy |
| PL17823018.1T PL3518933T5 (pl) | 2016-09-30 | 2017-09-29 | Metody leczenia mięśniaków macicy i endometriozy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17823018.1T PL3518933T5 (pl) | 2016-09-30 | 2017-09-29 | Metody leczenia mięśniaków macicy i endometriozy |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11033551B2 (enExample) |
| EP (2) | EP4094766B1 (enExample) |
| JP (1) | JP7043503B2 (enExample) |
| CN (1) | CN110312512B (enExample) |
| AU (2) | AU2017336363B2 (enExample) |
| BR (1) | BR112019006227A2 (enExample) |
| CA (1) | CA3038879A1 (enExample) |
| CY (1) | CY1125254T1 (enExample) |
| DK (1) | DK3518933T4 (enExample) |
| ES (2) | ES2912929T5 (enExample) |
| FI (1) | FI3518933T4 (enExample) |
| HR (1) | HRP20220708T4 (enExample) |
| HU (2) | HUE072130T2 (enExample) |
| IL (2) | IL300580B2 (enExample) |
| LT (1) | LT3518933T (enExample) |
| MD (1) | MD3518933T4 (enExample) |
| MX (1) | MX2019003726A (enExample) |
| NZ (1) | NZ752916A (enExample) |
| PL (2) | PL4094766T3 (enExample) |
| PT (1) | PT3518933T (enExample) |
| RS (1) | RS63300B2 (enExample) |
| SI (1) | SI3518933T2 (enExample) |
| SM (1) | SMT202200254T1 (enExample) |
| WO (1) | WO2018060501A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3518932T3 (da) | 2016-09-30 | 2025-01-27 | Takeda Pharmaceuticals Co | Behandling af prostatacancer |
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| AU2018419533A1 (en) * | 2018-04-19 | 2020-11-12 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
| WO2020089190A2 (en) * | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| RU2711658C1 (ru) * | 2019-04-16 | 2020-01-20 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" | Способ лечения наружного генитального эндометриоза |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| KR20220061120A (ko) * | 2019-08-08 | 2022-05-12 | 옵스에파 에스에이 | 에스트로겐-의존성 장애 치료용 조성물 및 방법 |
| JP7713934B2 (ja) * | 2019-10-10 | 2025-07-28 | スミトモ ファーマ スウィッツァーランド ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形 |
| WO2021069711A1 (en) * | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| WO2021168040A1 (en) * | 2020-02-19 | 2021-08-26 | Aspira Women's Health Inc. | Compositions for endometriosis assessment having improved specificity |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| MX2022015003A (es) * | 2020-05-29 | 2023-03-03 | Myovant Sciences Gmbh | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. |
| WO2022101303A1 (en) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| CN118451082A (zh) | 2021-10-18 | 2024-08-06 | 住友制药瑞士有限公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式 |
| CN117069735A (zh) * | 2022-05-10 | 2023-11-17 | 北京海美源医药科技有限公司 | 一种高效合成瑞卢戈利的方法和其应用 |
| WO2024015934A2 (en) * | 2022-07-13 | 2024-01-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of diagnostic screening and early detection of adenomyosis |
| TW202428262A (zh) * | 2022-11-09 | 2024-07-16 | 美商坦帕斯醫療公司 | 三唑酮化合物及其用途 |
| WO2025106820A1 (en) * | 2023-11-16 | 2025-05-22 | University Of South Florida | Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub) |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US402034A (en) | 1889-04-23 | Dumping-wagon | ||
| US402055A (en) | 1889-04-23 | Water-motor | ||
| US492839A (en) | 1893-03-07 | Key for brake-shoes | ||
| US528409A (en) | 1894-10-30 | Denis ahern | ||
| US402150A (en) | 1889-04-30 | Broadcast seed-sower | ||
| FR2512732A1 (fr) | 1981-09-14 | 1983-03-18 | Raffinage Cie Francaise | Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications |
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| ECSP961635A (es) | 1996-01-11 | 1997-06-27 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| ECSP971998A (es) | 1997-01-15 | 1998-04-07 | Desprendimiento controlado de esteroides del recubrimiento de azucar | |
| DE19815060A1 (de) | 1998-04-03 | 1999-10-14 | Jenapharm Gmbh | Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie |
| US6265393B1 (en) * | 1998-08-07 | 2001-07-24 | Heinrichs William Leroy | Prevention of endometriosis signs or symptons |
| US6297379B1 (en) | 1999-03-24 | 2001-10-02 | Takeda Chemical Industries, Ltd. | Thienopyrimidine compounds, their production and use |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| US6849738B2 (en) | 2000-02-29 | 2005-02-01 | Takeda Chemical Industries, Ltd. | Processes for the production of thienopyrimidine derivatives |
| US7569570B2 (en) | 2002-01-30 | 2009-08-04 | Takeda Pharmaceutical Company Limited | Thienopyrimidines, process for preparing the same and use thereof |
| ZA200506611B (en) | 2003-01-29 | 2006-12-27 | Takeda Pharmaceutical | Thienopyrimidine compounds and use thereof |
| WO2005007165A1 (en) | 2003-07-07 | 2005-01-27 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| MY151322A (en) | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| US20090048273A1 (en) | 2005-07-22 | 2009-02-19 | Takeda Pharmaceutical Company Limited | Premature ovulation preventive agent |
| AR058584A1 (es) | 2005-12-22 | 2008-02-13 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos |
| ES2534573T3 (es) | 2007-04-06 | 2015-04-24 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| JPWO2010026993A1 (ja) | 2008-09-03 | 2012-02-02 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| US9427418B2 (en) | 2009-02-23 | 2016-08-30 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
| KR101731008B1 (ko) | 2010-06-16 | 2017-04-27 | 앙도르쉐르슈 인코포레이티드 | 에스트로겐-관련 질병의 치료 또는 예방 방법 |
| JP2012077020A (ja) | 2010-09-30 | 2012-04-19 | Mochida Pharmaceut Co Ltd | ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬 |
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| IL241595B2 (en) * | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| FI4233847T3 (fi) | 2015-02-26 | 2024-09-24 | Takeda Pharmaceuticals Co | Metoksiureajohdannaista ja mannitolihiukkasia käsittävä tabletti |
| CA3002791A1 (en) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
| DK3518932T3 (da) | 2016-09-30 | 2025-01-27 | Takeda Pharmaceuticals Co | Behandling af prostatacancer |
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| JP7713934B2 (ja) | 2019-10-10 | 2025-07-28 | スミトモ ファーマ スウィッツァーランド ゲーエムベーハー | Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶溶媒和形 |
| WO2021069711A1 (en) | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea |
| MX2022015003A (es) | 2020-05-29 | 2023-03-03 | Myovant Sciences Gmbh | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. |
| WO2022101303A1 (en) | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| CN118451082A (zh) | 2021-10-18 | 2024-08-06 | 住友制药瑞士有限公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-N'-甲氧基脲的乙醇溶剂化物的结晶形式 |
-
2017
- 2017-09-29 SM SM20220254T patent/SMT202200254T1/it unknown
- 2017-09-29 AU AU2017336363A patent/AU2017336363B2/en active Active
- 2017-09-29 MX MX2019003726A patent/MX2019003726A/es unknown
- 2017-09-29 WO PCT/EP2017/074907 patent/WO2018060501A2/en not_active Ceased
- 2017-09-29 JP JP2019538721A patent/JP7043503B2/ja active Active
- 2017-09-29 CA CA3038879A patent/CA3038879A1/en active Pending
- 2017-09-29 NZ NZ752916A patent/NZ752916A/en unknown
- 2017-09-29 FI FIEP17823018.1T patent/FI3518933T4/fi active
- 2017-09-29 PL PL22162349.9T patent/PL4094766T3/pl unknown
- 2017-09-29 HR HRP20220708TT patent/HRP20220708T4/hr unknown
- 2017-09-29 HU HUE22162349A patent/HUE072130T2/hu unknown
- 2017-09-29 EP EP22162349.9A patent/EP4094766B1/en active Active
- 2017-09-29 LT LTEPPCT/EP2017/074907T patent/LT3518933T/lt unknown
- 2017-09-29 PT PT178230181T patent/PT3518933T/pt unknown
- 2017-09-29 MD MDE20190880T patent/MD3518933T4/ro unknown
- 2017-09-29 BR BR112019006227-0A patent/BR112019006227A2/pt unknown
- 2017-09-29 RS RS20220565A patent/RS63300B2/sr unknown
- 2017-09-29 ES ES17823018T patent/ES2912929T5/es active Active
- 2017-09-29 CN CN201780072987.XA patent/CN110312512B/zh active Active
- 2017-09-29 HU HUE17823018A patent/HUE059101T2/hu unknown
- 2017-09-29 PL PL17823018.1T patent/PL3518933T5/pl unknown
- 2017-09-29 IL IL300580A patent/IL300580B2/en unknown
- 2017-09-29 EP EP17823018.1A patent/EP3518933B2/en active Active
- 2017-09-29 SI SI201731123T patent/SI3518933T2/sl unknown
- 2017-09-29 DK DK17823018.1T patent/DK3518933T4/da active
- 2017-09-29 ES ES22162349T patent/ES3018413T3/es active Active
-
2019
- 2019-03-28 IL IL265700A patent/IL265700B2/en unknown
- 2019-03-29 US US16/370,299 patent/US11033551B2/en active Active
-
2021
- 2021-05-11 US US17/317,769 patent/US11793812B2/en active Active
-
2022
- 2022-06-02 CY CY20221100390T patent/CY1125254T1/el unknown
- 2022-07-15 US US17/866,201 patent/US11957684B2/en active Active
- 2022-09-30 AU AU2022241582A patent/AU2022241582C1/en active Active
-
2024
- 2024-01-30 US US18/427,579 patent/US20240165118A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE072130T2 (hu) | Orális rögzített dózisú kombináció és annak felhasználása méhmióma és endometriosis kezelésében | |
| IL262354A (en) | Ultrasound treatment and imaging device | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| SMT202500469T1 (it) | Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla | |
| ZA201900777B (en) | Usage and dosage of therapeutic agents for endometriosis | |
| ZA201704726B (en) | Peptides and their use in the treatment of skin | |
| SG11201801981UA (en) | Therapeutic substance delivery device and therapeutic substance delivery kit | |
| IL273470A (en) | Semaglutide in medical treatment | |
| GB201715194D0 (en) | Compounds and their therapeutic use | |
| GB201604213D0 (en) | Drug combination and its use in therapy | |
| IL244573A0 (en) | Preparations containing peptides and their use for the treatment of oral mucositis | |
| IL271327A (en) | Compositions and methods for enhancing hyperthermic therapy | |
| ZA201508050B (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| SMT202200151T1 (it) | Composizioni e metodi per l’uso nel trattamento di omocistinuria. | |
| IL273863B1 (en) | Hemorrhoid treatment device | |
| ZA201600312B (en) | Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders | |
| IL261182B (en) | Leptin antagonist for use in the treatment of ischemia and reperfusion injury | |
| PL3341481T3 (pl) | Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne | |
| GB201410869D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| PT3664800T (pt) | Formulações terapêuticas que compreendem inibidor da cox-2 e utilizações das mesmas | |
| SG11201802955VA (en) | Peptides of use in the preventive and curative treatment of alopecia | |
| SMT202100673T1 (it) | Composizione per uso odontoiatrico e relativa apparecchiatura per la cura del cavo orale | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |